Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in ...

For Biogen, an expensive gamble has paid off, as even with accelerated approval the company stands to make billions of dollars from aducanumab, given it estimates there are around 1.5 million ...

Alzheimer's deal renegotiated Meanwhile Biogen has one of the most keenly anticipated drug candidates in its pipeline, early Alzheimer’s treatment aducanumab. The firm has just renegotiated its ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.8 ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

Biogen Pharmachem Industries Limited is an India-based company, which is not engaged in any activity. The Company is looking for the right opportunity to make the Company operational. What is the ...

A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year. Although it ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.

Dividend announcements are not available.